Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
The Lancet. Oncology
|
April 7, 2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Sarah B Goldberg, Kurt A Schalper, Scott N Gettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
William J Magnuson, Nataniel H Lester-Coll, Abraham J Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Nature
|
November 28, 2014
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S Herbst, Jean-Charles Soria, Marcin Kowanetz, et al.
The Lancet. Oncology
|
April 7, 2020
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
Sarah B Goldberg, Kurt A Schalper, Scott N Gettinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 12, 2020
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
JTO Clinical and Research Reports
|
September 6, 2022
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory <i>ALK</i>+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Scott N Gettinger, Rudolf M Huber, Dong-Wan Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2017
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis
William J Magnuson, Nataniel H Lester-Coll, Abraham J Wu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 10, 2018
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)
Marcin Kowanetz, Wei Zou, Scott N Gettinger, et al.
The New England Journal of Medicine
|
October 4, 2018
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, et al.
The New England Journal of Medicine
|
September 29, 2015
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Hossein Borghaei, Luis Paz-Ares, Leora Horn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 3, 2016
The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer
Vassiliki Papadimitrakopoulou, J Jack Lee, Ignacio I Wistuba, et al.
Page
of 7